Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT

The Real World Evidence revolution

We focus on pragmatic Real-World Evidence (RWE) studies for generating clinically meaningful meaningful data and physician experience faster, unlocking the true potential of these transformational therapies sooner.

We believe it’s the best way to ensure rapid, safe and appropriate access to reimbursed psilocybin therapy.

Driving positive mental health change

Psilocybin-based medicines could change the way mental health is treated, and as a result, we believe the human experience as a whole will improve.

Current mental health treatments are decades old, relatively ineffective and can come with severe side effects. New approaches to antidepressants have failed, and major pharma has abandoned R&D in CNS research. [1] 

Our Team

1 Billion people suffer worldwide

from anxiety and depression disorders worldwide [2]

Costs $1 trillion/yr globally

depression and anxiety, cost the global economy $1 trillion each year [3]

13% Rise in mental health conditions

in mental health conditions and substance use disorders in the last decade [4]

Psychotherapy in combination with KRN-101

Psilocybin therapy is a paradigm shift away from the traditional approaches such as antidepressants. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support.

Leading academics are demonstrating success with psilocybin as well as other psychoactive psychedelic medicines as therapy for treatment-resistant depression, anxiety, drug addiction and much more.

The Unmet Need

KRN-101

Psychological
Support

Our Clinical Program

Albert Labs are conducting a rigorous, large-scale clinical development programme of KRN-101 psilocybin therapy for cancer related distress across the UK and Europe.

Preparation

In these first preparation sessions, an Albert Labs therapist will get to know you closely and form a trusting relationship.  The focus will be on establishing a therapeutic alliance between the therapist and participant. 

During preparation, the therapist aims to build the participant’s capacity to navigate distressing experiences through self-directed enquiry and experiential processing. Practising this approach during preparation helps prepare the participant to engage with their experiences in the psilocybin session.

Dosing session

During the psilocybin session, the focus is on facilitating a meaningful experience. Patients listen to crafted music playlists and wear an eye mask. This helps the participant to focus internally. The psilocybin experience typically lasts 6-8 hours, and the participant is encouraged to maintain a courageous, trusting and open attitude in order to move “in and through” the full range of internal experiences. Albert Labs’ therapists maintain the same attitudes of openness and interest toward participants.

Integration

The therapeutic focus of integration is to reflect on the experience and generate insights following the psilocybin session. Participants are encouraged to describe and connect with the range of emotional, cognitive and physical experiences of the psilocybin session and relate them to their personal narratives. The integration process will generally unfold over time as the participant begins to implement changes in their life based on the experiences and insights of their psilocybin session.

– November 30, 2016

1. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer

Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby and Brian L Schmidt.

Read more

– November 30, 2016

2. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

Roland R Griffiths, Matthew W Johnson1, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano and Margaret A Klinedinst.

Read more

– September 6, 2010

3. Psilocybin treatment for anxiety in patients with advanced-stage cancer

Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer.

Read more

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2022 Albert Labs. All Rights Reserved

  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact investing@albertlabs.com

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

Twitter
Youtube
Linkedin
Instagram
Envelope

Latest Press Release

Albert Labs Announces Private Placement

Read more
Twitter
Youtube
Linkedin
Instagram
Envelope

Latest Press Release

Albert Labs Announces Private Placement

Read more

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok